Meixiao Long News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Apr 09, 2021
Median Duration of Response Not Reached at 28.1 Months of Median Study Follow Up in Cohort 2 of C-144-01 Study
36.4% Overall Response Rate; Continued Deepening of Responses
SAN CARLOS, Calif., April 09, 2021 (GLOBE NEWSWIRE)
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma. These data will be part of an oral presentation in a Clinical Trials Plenary Session at the upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting.
“We are very excited to report our latest Cohort 2 melanoma data in an oral presentation at AACR,” said Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics. “The long term follow up data show that median duration of response was not reached at 28.1 months of median study follow u ....

United States , Jason Chesney , Jason Alan Chesney , Zara Lockshin , Erminia Massarelli , Maria Fardis , Sara Pellegrino , Scott Gettinger , Iovance Biotherapeutics , Exchange Commission , James Graham Brown Cancer Center , American Association For Cancer Research , Iovance Biotherapeutics Inc , Drug Administration , University Of Louisville , Median Duration , Response Not Reached , Overall Response Rate , Continued Deepening , Clinical Trials Plenary Session , American Association , Cancer Research , Chief Executive Officer , Meeting Planner , Cell Therapy , Annual Meeting ,